Albert J. Augustin, MD, discusses the BEVORDEX trial, which compared bevacizumab (Avastin, Genentech) with the dexamethasone intravitreal implant 0.7 mg (Ozurdex, Allergan). Dr. Augustin also shares the results of studies that evaluated the efficacy of switching from anti-VEGF therapy to either the dexamethasone implant or the fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien, Alimera Science) in cases of recalcitrant disease.
Anti-VEGF • Diabetic macular edema, DME • Steroids
11 / 12 Series: 2018 Euretina Meeting
post as anonymous